BRANDI MEADS: Open Payments
NPI 1447623038 · OXFORD, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,248 in 141 payments from 22 companies in 2025. Trend: 2023 $2,322 · 2024 $3,119 · 2025 $2,248
Food & beverage: $2,248
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $418 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 33 | $364 |
| Novo Nordisk Inc | 13 | $223 |
| Vanda Pharmaceuticals Inc. | 8 | $197 |
| Otsuka America Pharmaceutical, Inc. | 8 | $153 |
| Braeburn Inc. | 7 | $133 |
| Axsome Therapeutics, Inc. | 5 | $114 |
| Atland Pharmaceuticals, LLC | 1 | $92 |
| Indivior Inc. | 3 | $64 |
| Antares Pharma, Inc. | 3 | $60 |
Products named: CAPLYTA, VRAYLAR, FANAPT, REXULTI, BRIXADI, Auvelity, UBRELVY, Ozempic.
Industry payments across AL — which companies pay providers there.
